1. Home
  2. TNON vs GRDX Comparison

TNON vs GRDX Comparison

Compare TNON & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$0.78

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.00

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TNON
GRDX
Founded
2012
N/A
Country
United States
United Kingdom
Employees
27
2
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
7.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNON
GRDX
Price
$0.78
$2.00
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
154.3K
106.6K
Earning Date
03-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.93
N/A
Revenue Next Year
$48.34
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$1.87
52 Week High
$3.26
$5.30

Technical Indicators

Market Signals
Indicator
TNON
GRDX
Relative Strength Index (RSI) 44.96 39.42
Support Level $0.72 $2.03
Resistance Level $0.91 $2.56
Average True Range (ATR) 0.06 0.21
MACD 0.00 0.01
Stochastic Oscillator 19.96 26.09

Price Performance

Historical Comparison
TNON
GRDX

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: